---
title: "Tharimmune Inc. Files Initial Statement of Beneficial Ownership for Director Jill E. Sommers"
description: "Tharimmune Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission, listing Jill E. Sommers as a director. The full filing is accessible v"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275667458.md"
published_at: "2026-02-11T22:19:05.000Z"
---

# Tharimmune Inc. Files Initial Statement of Beneficial Ownership for Director Jill E. Sommers

> Tharimmune Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission, listing Jill E. Sommers as a director. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

Tharimmune Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing lists Jill E. Sommers as a director of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-006240), on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [THAR.US - Tharimmune](https://longbridge.com/en/quote/THAR.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fate Therapeutics 第四季度财报总结及主要内容 | Fate Therapeutics（纳斯达克代码：FATE）于 2026 年 2 月 26 日公布了第四季度财报，实际每股收益（EPS）为-0.27，未能达到预期。与去年相比，收入减少了 491,000 美元。在上一个季度，公司每股收益超出 | [Link](https://longbridge.com/en/news/277057214.md) |
| 关键事实：ImmunityBio 已完成第二阶段试验的招募工作；电话会议已安排 | ImmunityBio 已经提前完成了其第二阶段 Quilt 2.005 试验的招募，该试验评估 Anktiva 和 BCG 对早期膀胱癌的疗效，显示出改善的无癌率。ImmunityBio, Inc. 将于 2026 年 3 月 3 日下午 | [Link](https://longbridge.com/en/news/277243866.md) |
| Q32 Bio（纳斯达克股票代码：QTTB）的内部人士 Shelia Violette 出售了 2,815 股股票 | Q32 Bio Inc. 的内部人士 Shelia Violette 出售了 2,815 股，每股售价为 4.51 美元，总计 12,695.65 美元，减少了她的持股比例 4.82%。首席执行官 Jodie Pope Morrison 在 | [Link](https://longbridge.com/en/news/277313384.md) |
| ImmunityBio 的董事出售了 75,000 股股票 | ImmunityBio 董事 Simon Barry J. 于 2026 年 2 月 24 日以每股平均价格 12.0105 美元出售了 75,000 股普通股，总计 900,787 美元。此次出售是在 2024 年 9 月 4 日建立的  | [Link](https://longbridge.com/en/news/277125041.md) |
| Ocular Therapeutix, Inc.（NASDAQ 代码：OCUL）被分析师给予 “适度买入” 的平均评级 | Ocular Therapeutix, Inc.（纳斯达克代码：OCUL）获得了十四家研究公司的 “适度买入” 共识评级。平均 12 个月目标价为 23.78 美元，其中十二位分析师建议买入，一位建议持有，一位建议卖出。该公司报告的季度每股 | [Link](https://longbridge.com/en/news/277281052.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.